Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul G. Richardson is active.

Publication


Featured researches published by Paul G. Richardson.


Cancer Cell | 2014

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Jens Lohr; Petar Stojanov; Scott L. Carter; Peter Cruz-Gordillo; Michael S. Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael Chapman; Ravid Straussman; Joan Levy; Louise M. Perkins; Jonathan J. Keats; Steven E. Schumacher; Mara Rosenberg; Kenneth C. Anderson; Paul G. Richardson; Amrita Krishnan; Sagar Lonial; Jonathan L. Kaufman; David Siegel; David H. Vesole; Vivek Roy; Candido E. Rivera; S. Vincent Rajkumar; Shaji Kumar

We performed massively parallel sequencing of paired tumor/normal samples from 203 multiple myeloma (MM) patients and identified significantly mutated genes and copy number alterations and discovered putative tumor suppressor genes by determining homozygous deletions and loss of heterozygosity. We observed frequent mutations in KRAS (particularly in previously treated patients), NRAS, BRAF, FAM46C, TP53, and DIS3 (particularly in nonhyperdiploid MM). Mutations were often present in subclonal populations, and multiple mutations within the same pathway (e.g., KRAS, NRAS, and BRAF) were observed in the same patient. In vitro modeling predicts only partial treatment efficacy of targeting subclonal mutations, and even growth promotion of nonmutated subclones in some cases. These results emphasize the importance of heterogeneity analysis for treatment decisions.


Archive | 2011

Bortezomib in the treatment of multiple myeloma

Im Ghobrial; Paul G. Richardson; Kenneth C. Anderson

Bortezomib in the treatment of multiple myeloma , Bortezomib in the treatment of multiple myeloma , کتابخانه دیجیتال جندی شاپور اهواز


Archive | 2017

Vaccination with DC/tumor fusion cells results in cellular and humoral anti-tumor immune responses in patients with multiple myeloma DC/myeloma fusion vaccine induces immune responses

Jacalyn Rosenblatt; Baldev Vasir; Lynne Uhl; Simona Blotta; Claire MacNamara; Poorvi Somaiya; Zekui Wu; Robin M. Joyce; James D. Levine; Dilani Dombagoda; Yan Emily Yuan; Karen Francoeur; Donna Fitzgerald; Paul G. Richardson; Edie Weller; Kenneth C. Anderson; Donald Kufe; Nikhil C. Munshi; David Avigan


Archive | 2017

CLINICAL TRIALS AND OBSERVATIONS Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia

Im Ghobrial; Federico Campigotto; Timothy J. Murphy; Erica N Boswell; Ranjit Banwait; Feda Azab; Stacey Chuma; Janet Kunsman; Amanda Donovan; Farzana Masood; Diane Warren; Scott J. Rodig; Kenneth C. Anderson; Paul G. Richardson; Edie Weller; Jeffrey Matous


Archive | 2016

AdenosineA2Areceptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies

Richard Rickles; Laura T. Pierce; Thomas P. Giordano; Winnie F. Tam; Douglas W. McMillin; Jake Delmore; Jacob Laubach; Alexis Borisy; Paul G. Richardson; Margaret S. Lee


Archive | 2013

therapeutic option in multiple myeloma is a promising α Blockade of XBP1 splicing by inhibition of IRE1

Kenneth C. Anderson; Tuan Pham; Qingping Zeng; John B. Patterson; Paul G. Richardson; Nikhil C. Munshi; Maureen French; Martina Blumenthal; Victor Tam; Nathalie L. Kertesz; Uriel M. Malyankar; Yiguo Hu; Claire Fabre; Jiro Minami; Hiroto Ohguchi; Tanyel Kiziltepe; Hiroshi Ikeda; Mariateresa Fulciniti; Gullu Gorgun; Diana Cirstea; Loredana Santo


Archive | 2013

marrow milieu Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone

Dharminder Chauhan; Kenneth C. Anderson; Teru Hideshima; Masaharu Akiyama; Toshiaki Hayashi; Paul G. Richardson; Robert L. Schlossman


Archive | 2013

specific cytotoxic T lymphocytes - Ex vivo induction of multiple myeloma

Kenneth C. Anderson; Toshiaki Hayashi; Teru Hideshima; Masaharu Akiyama; Noopur Raje; Paul G. Richardson


Archive | 2013

bortezomib with refractory multiple myeloma who have received lenalidomide and Phase 1 study of pomalidomide MTD, safety, and efficacy in patients

Min Chen; Mohamad H. Zaki; Christian Jacques; Laura McBride; Elizabeth Bilotti; Palka Anand; Lisa Nardelli; Gail Larkins; Daniel C. Sullivan; Melissa Alsina; Robert L. Schlossman; Im Ghobrial; Deborah Doss; Paul G. Richardson; David S. Siegel; Rachid Baz; Susan L. Kelley; Nikhil C. Munshi; Jacob Laubach


Archive | 2013

microenvironment migration of multiple myeloma cells in the bone marrow GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and

Teru Hideshima; Dharminder Chauhan; Kenneth C. Anderson; Renate Burger; Robert L. Schlossman; Paul G. Richardson; Lini Pandite; Laurence Catley; Reshma Shringarpure; Pedro Carvalho

Collaboration


Dive into the Paul G. Richardson's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Teru Hideshima

VA Boston Healthcare System

View shared research outputs
Top Co-Authors

Avatar

Sagar Lonial

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Klaus Podar

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David H. Vesole

Hackensack University Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge